Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia
(WorldNews Business)

BOSTON--(BUSINESS WIRE)--Jun 13, 2019-- Follica, Inc. (`Follica`), a clinical-stage biotech developing a regenerative platform for hair growth, today announced positive interim data from an ongoing safety and optimization study to treat hair loss in male androgenetic alopecia. In addition to being well tolerated and informing key treatment parameters, analysis of 20 male study participants with androgenetic alopecia showed that Follica´s approach achieved a visible and statistically significant improvement in non-vellus (visible) hair count after three months of treatment, compared to baseline. Additionally, blinded head-to-head bench testing of the proprietary Follica device has shown...